Research advances in pituitary adenylate cyclase activating polypeptide 38 and migraine
10.19845/j.cnki.zfysjjbzz.2025.0208
- VernacularTitle:垂体腺苷酸环化酶激活肽38与偏头痛的研究进展
- Author:
Xinyu YAN
1
;
Dongjun WAN
2
Author Information
1. 西北民族大学医学部，甘肃 兰州 730030
2. 联勤保障部队第九四〇医院神经内科，甘肃 兰州 730050
- Publication Type:Journal Article
- Keywords:
Neuropeptide;
Pituitary adenylate cyclase activating polypeptide;
Migraine;
Targeted therapy
- MeSH:
Neuropeptides
- From:
Journal of Apoplexy and Nervous Diseases
2025;42(12):1150-1152
- CountryChina
- Language:Chinese
-
Abstract:
Pituitary adenylate cyclase activating polypeptide（PACAP）， as an important neuropeptide， plays a key role in the pathophysiological process of migraine. Although current anti-（calcitonin gene-related peptide，CGRP） targeted therapy has become a major breakthrough in migraine treatment， some patients show suboptimal responses to anti-CGRP therapy. In recent years， PACAP-38 has attracted significant attention as a potential novel therapeutic target. This article systematically reviews the molecular characteristics of PACAP-38， its pathological association with migraine， and the latest research advances in related targeted drugs， in order to provide new ideas for the precise treatment of migraine.
- Full text:2026012308493316785垂体腺苷酸环化酶激活肽38与偏头痛的研究进展.pdf
